focus -WSS

focus

author：knowledge 2025-09-30 23:40:13 - browse：96326

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Drug repurposing or repositioning? The language matters

WSS

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Guidelines to prevent youth baseball injuries need more muscle

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Shifting the focus from loneliness to social health

See how much Covid

focus

focus

explore

Moonlake's readout produced a cash windfall. Risks remain

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cancer drug shortages should be causing more outrage

New air purifier tech could be key to improving indoor air quality

Guidelines to prevent youth baseball injuries need more muscle

Medical leaders decry Supreme Court decision on affirmative action

Drug repurposing or repositioning? The language matters

Hepatitis C has a cure — but many Americans still lack access to it

Medicare details structure of new drug price negotiation program

explore

Affirmative action in medical school literally saved lives

NIH documents show early flaws of $1.6 billion long Covid program

Peter Hotez and the public health issue of online harassment

Supreme Court strikes down use of affirmative action

See how much Covid

Ultragenyx gene therapy for rare liver ailment succeeds in late

Wikipedia

leisure time

hotspot

focus